Personalized prognosis in unresectable hepatocellular carcinoma: Development and validation of a model for transcatheter arterial chemoembolization plus lenvatinib

Table 1 The β-coefficient and score for overall survival prediction model

Risk factors	Pooled HR	95%CI	β-coefficient	Score
Number of tumors
Single	Reference1			0
Multiple	1.22	1.06-1.40	0.199	2
Microvascular invasion
No	Reference1			0
Yes	1.61	1.41-1.85	0.476	5
ECOG performance status
≤ 0	Reference1			0
> 0	1.30	1.12-1.52	0.262	2.5
Child-Pugh stage
≤ A	Reference1			0
> A	1.48	1.26-1.74	0.392	4
Triple therapy
TACE + LEN	Reference1			0
TACE + LEN + PD-1	0.41	0.36-0.46	-0.892	-9
BCLC stage
≤ B	Reference1			0
> B	1.77	1.51-2.08	0.571	6
Extrahepatic metastases
No	Reference1			0
Yes	1.40	1.23-1.60	0.336	3.5
AFP
< 400 ng/mL	Reference1			0
≥ 400 ng/mL	1.55	1.40-1.72	0.438	4.5
HBV
Negative	Reference1			0
Positive	1.36	1.17-1.58	0.307	3

¹Reference group.

ECOG: Eastern Cooperative Oncology Group; TACE: Transcatheter arterial chemoembolization; LEN: Lenvatinib; PD-1: Programmed death-1; BCLC: Barcelona Clinic Liver Cancer; AFP: Alpha-fetoprotein; HBV: Hepatitis B virus; HR: Hazard ratio; CI: Confidence interval.

Table 2 The β-coefficient and score for progression-free survival prediction model

Risk factors	Pooled HR	95%CI	β-coefficient	Score
Number of tumors
Single	Reference1			0
Multiple	1.23	1.07-1.40	0.207	2
Microvascular invasion
No	Reference1			0
Yes	1.38	1.18-1.62	0.322	3
ECOG performance status
≤ 0	Reference1			0
> 0	1.27	1.14-1.42	0.239	2.5
Child-Pugh stage
≤ A	Reference1			0
> A	1.45	1.23-1.70	0.372	4
Triple therapy
TACE + LEN	Reference1			0
TACE + LEN + PD-1	0.45	0.39-0.53	-0.799	-8
BCLC stage
≤ B	Reference1			0
> B	1.36	1.15-1.60	0.307	3
Extrahepatic metastases
No	Reference1			0
Yes	1.26	1.07-1.50	0.231	2.5
AFP
< 400 ng/mL	Reference1			0
≥ 400 ng/mL	1.28	1.16-1.41	0.247	2.5
HBV
Negative	Reference1			0
Positive	1.18	1.02-1.36	0.166	1.5

¹Reference group.

ECOG: Eastern Cooperative Oncology Group; TACE: Transcatheter arterial chemoembolization; LEN: Lenvatinib; PD-1: Programmed death-1; BCLC: Barcelona Clinic Liver Cancer; AFP: Alpha-fetoprotein; HBV: Hepatitis B virus; HR: Hazard ratio; CI: Confidence interval.